Molecular Basis and Treatment of Cardiac Arrhythmias

心律失常的分子基础和治疗

基本信息

  • 批准号:
    8467016
  • 负责人:
  • 金额:
    $ 32.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-21 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY / ABSTRACT A major cause of sudden death in patients with heart failure (HF) is ventricular arrhythmia. Disappointingly, large clinical trials have recently demonstrated that most of the anti-arrhythmic drugs have little or no survival benefits. Surprisingly, ¿-blockers, once thought to be dangerous and contraindicated for patients with HF, have consistently been shown to reduce the risk of sudden death. However, the molecular mechanisms underlying ¿-blockers' survival benefits are unknown. The overall objective of this proposal is to understand the beneficial effects of ¿-blockers and to develop novel anti-arrhythmic agents. It is well known that spontaneous Ca2+ release, also known as store-overload-induced-Ca2+-release (SOICR), can cause delayed afterdepolarizations (DADs), which in turn can trigger arrhythmias. Importantly, enhanced SOICR activity and DAD-associated ventricular arrhythmias are common in HF and in cardiac ryanodine receptor (RyR2)-associated ventricular arrhythmias. Hypotheses: the beneficial effects of ¿-blockers are, in part, attributable to SOICR inhibition, and that SOICR inhibitors are effective in suppressing cardiac arrhythmias. Three specific aims are proposed. 1. To Assess the Impact of Different ¿-blockers on Spontaneous Ca2+ Release or SOICR and RyR2-Associated Arrhythmias. The impact of a number of ¿- blockers on SOICR, the activity of RyR2, and stress-induced ventricular arrhythmias will be determined using various approaches. 2. To Design, Synthesize, and Characterize Novel Carvedilol Analogues for Suppressing Arrhythmias. Our preliminary data demonstrate that carvedilol is uniquely effective among ¿- blockers in suppressing SOICR. To improve its efficacy and to produce a novel class of anti-arrhythmic agents, a number of carvedilol derivatives will be synthesized in order to reduce or diminish its ¿-blocking activity, while retaining or increasing its SOICR inhibition. 3. To Understand the Molecular Basis of SOICR. Site-directed mutagenesis in conjunction with single channel analysis will be used to test our hypothesis that SOICR is governed by a luminal Ca2+ sensor located within the RyR2 channel pore. Significance: These proposed studies will not only shed novel mechanistic insight into the molecular basis of cardiac arrhythmias, but also lead to the development of a new and promising class of anti-arrhythmic agents, and have direct implications for the prevention and treatment of cardiac arrhythmias.
项目总结/摘要 心力衰竭(HF)患者猝死的一个主要原因是室性心律失常。令人困惑的是, 最近的大型临床试验表明,大多数抗疟疾药物很少或没有 生存福利。令人惊讶的是,曾经被认为是危险和禁忌的药物, 与HF,一直被证明可以降低猝死的风险。然而,分子 阻断剂的生存益处的潜在机制尚不清楚。本建议的总体目标是 了解β-受体阻滞剂的有益作用,并开发新型抗肿瘤药物。公 已知自发性Ca 2+释放,也称为钙库超载诱导Ca 2+释放(SOICR),可 导致延迟后除极(DAD),这反过来又会引发心律失常。重要的是,增强 SOICR活性和DAD相关的室性心律失常在HF和心脏ryanodine中很常见 RyR 2受体相关的室性心律失常。假设:阻断剂的有益效果是, 部分,归因于SOICR抑制,并且SOICR抑制剂有效抑制心脏 心律不齐提出了三个具体目标。1.评估不同受体阻滞剂对 自发性Ca 2+释放或SOICR和RyR 2相关心律失常。一系列的影响- 将测定SOICR、RyR 2活性和应激诱导的室性心律失常的阻滞剂 使用各种方法。2.卡维地洛类似物的设计、合成和表征 抑制心律失常。我们的初步数据表明,卡维地洛是唯一有效的, 抑制SOICR的阻断剂。为了提高其功效并产生一类新型的抗肿瘤药物, 为了降低或减弱其阻断作用,将合成许多卡维地洛衍生物 活性,同时保持或增加其SOICR抑制。3.了解SOICR的分子基础。 定点诱变结合单通道分析将用于检验我们的假设, SOICR由位于RyR 2通道孔内的管腔Ca 2+传感器控制。意义:这些 拟议的研究不仅将揭示心脏病的分子基础的新机制, 心律失常,而且还导致一类新的和有前途的抗心律失常剂的发展, 对心律失常的预防和治疗有直接影响。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor.
  • DOI:
    10.1042/bj20080489
  • 发表时间:
    2008-09-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kong H;Jones PP;Koop A;Zhang L;Duff HJ;Chen SR
  • 通讯作者:
    Chen SR
Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice.
  • DOI:
    10.1161/circresaha.113.301678
  • 发表时间:
    2013-08-16
  • 期刊:
  • 影响因子:
    20.1
  • 作者:
    Bai Y;Jones PP;Guo J;Zhong X;Clark RB;Zhou Q;Wang R;Vallmitjana A;Benitez R;Hove-Madsen L;Semeniuk L;Guo A;Song LS;Duff HJ;Chen SR
  • 通讯作者:
    Chen SR
Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.
  • DOI:
    10.1021/jm401090a
  • 发表时间:
    2013-11-14
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Smith CD;Wang A;Vembaiyan K;Zhang J;Xie C;Zhou Q;Wu G;Chen SR;Back TG
  • 通讯作者:
    Back TG
Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis.
  • DOI:
    10.1161/circresaha.110.226845
  • 发表时间:
    2011-04-01
  • 期刊:
  • 影响因子:
    20.1
  • 作者:
    Priori SG;Chen SR
  • 通讯作者:
    Chen SR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUI RONG WAYNE CHEN其他文献

SUI RONG WAYNE CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUI RONG WAYNE CHEN', 18)}}的其他基金

Control of IP3R-Mediated Calcium Release
IP3R 介导的钙释放的控制
  • 批准号:
    8881893
  • 财政年份:
    2015
  • 资助金额:
    $ 32.54万
  • 项目类别:
Control of IP3R-Mediated Calcium Release
IP3R 介导的钙释放的控制
  • 批准号:
    9285819
  • 财政年份:
    2015
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
  • 批准号:
    7918945
  • 财政年份:
    2009
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
  • 批准号:
    7649038
  • 财政年份:
    2009
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
  • 批准号:
    8116555
  • 财政年份:
    2009
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
  • 批准号:
    8317617
  • 财政年份:
    2009
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
  • 批准号:
    7264633
  • 财政年份:
    2005
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
  • 批准号:
    6927656
  • 财政年份:
    2005
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
  • 批准号:
    7484210
  • 财政年份:
    2005
  • 资助金额:
    $ 32.54万
  • 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
  • 批准号:
    7080469
  • 财政年份:
    2005
  • 资助金额:
    $ 32.54万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 32.54万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 32.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 32.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 32.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 32.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 32.54万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 32.54万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 32.54万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 32.54万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 32.54万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了